Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials
Reuters2026/08/10 11:17- Aquestive Therapeutics published supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program.
- Resubmission human factors study in 105 untrained participants showed fewer use issues versus the original NDA study, including median open time cut to 3 seconds.
- PK study in healthy subjects showed self-administration comparable to clinician administration, with geometric mean Cmax 391.7 pg/mL vs 357.6 pg/mL.
- Purposeful top-of-tongue misplacement produced lower exposure, with geometric mean Cmax 112.7 pg/mL, while showing a clinically meaningful pharmacodynamic response.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
European cyclical stocks may see a rebound! Citi makes a major statement: The worst may be over, autumn is the perfect time to invest
Beata Manthey, Head of European Equity Strategy at Citigroup, stated that after a challenging period, European cyclical stocks—which are closely related to the health of the economy—now offer a rather attractive entry point.
Goldman Sachs cuts ADTRAN stake to 3.9% from 5.95% voting rights disclosure shows
British Pound pulls back from session highs as BoE Bailey tames rate hike hopes
Zcash Surges Above $1,000 to a New All-Time High
Crypto prices
More
